Compare SOWG & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOWG | PMVP |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | 54 |
| Industry | Packaged Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.9M | 72.2M |
| IPO Year | 2011 | 2020 |
| Metric | SOWG | PMVP |
|---|---|---|
| Price | $2.31 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 5.3K | ★ 554.8K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $1.02 |
| 52 Week High | $15.90 | $1.91 |
| Indicator | SOWG | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 46.41 |
| Support Level | $2.10 | $1.24 |
| Resistance Level | $2.62 | $1.31 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 82.29 | 51.90 |
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.